FDA approves tovorafenib, the first systemic therapy for BRAF-altered pediatric low-grade glioma

Later-Stage HumanFDA-approved for the exact stated cancer/useNot addressed

The FDA granted accelerated approval to tovorafenib (Ojemda), a type II RAF kinase inhibitor, for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG, the most common type of childhood brain tumor) harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation — the first systemic (whole-body) therapy ever approved specifically for this population. The approval was based on the single-arm, open-label, phase 2 FIREFLY-1 trial (ClinicalTrials.gov NCT04775485; primary publication in Nature Medicine, DOI 10.1038/s41591-023-02668-y, PMID 37978284), which enrolled patients aged 6 months to 25 years with relapsed or refractory disease and an activating BRAF alteration. In the 76-patient efficacy population, tumors shrank or resolved (an objective response) in about 67% of patients, with a median duration of response of 16.6 months.

What This Means

In the single-arm, phase 2 FIREFLY-1 trial, tovorafenib produced an objective response (tumor shrinkage or resolution) in about 67% of children and young adults with relapsed or refractory, BRAF-altered pediatric low-grade glioma who had already tried at least one prior systemic therapy — this is the first systemic (whole-body, non-surgical/non-radiation) therapy the FDA has ever approved specifically for this population.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group, supporting an ACCELERATED approval, not yet full/traditional approval — continued approval may depend on results from a confirmatory trial. This record makes no comparison to surgery, radiation, or other systemic options, and no claim about long-term survival, which was not this trial's design.

Why It Matters

Pediatric low-grade glioma is the most common type of childhood brain tumor, and until this approval there was no FDA-approved systemic drug therapy specifically for children whose tumors progressed despite prior treatment — this closes a real, previously-total treatment gap for this population.

Promise & Proof

Proof — strength of the evidence 5 / 5

Base score from evidence stage: Later-Stage Human.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Patients 6 months to 25 years old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation, who had received at least one prior systemic therapy, enrolled in the single-arm, open-label FIREFLY-1 trial. (Mixed / all ages)

Restricted to patients with a confirmed BRAF fusion/rearrangement or BRAF V600 mutation (biomarker testing required) and prior systemic therapy — not a first-line or universal pediatric-glioma treatment. This record has not independently reviewed the full pediatric safety/tolerability profile, which should be added before publication given this is a therapy used in children.

Full evidence details

Study design: Non-randomized trial
Sample size: 76

Funding & Conflicts

Sponsor/developer: Day One Biopharmaceuticals, Inc. — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.
Biomarker requirement: BRAF fusion/rearrangement or BRAF V600 mutation
Decision date: 2024-04-23
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

FIREFLY-1 trial primary results: tovorafenib in relapsed/refractory pediatric low-grade glioma (Nature Medicine) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 10.1038/s41591-023-02668-y Load-bearing source DOI 10.1038/s41591-023-02668-y, PMID 37978284
FIREFLY-1 trial primary results: tovorafenib in relapsed/refractory pediatric low-grade glioma (Nature Medicine). DOI 10.1038/s41591-023-02668-y, PMID 37978284.

Additional context

FIREFLY-1 trial registry (opens in a new tab) (Clinical-trial registry) NCT04775485 NCT04775485
FIREFLY-1 trial registry. NCT04775485.

Why Should I Trust This?

1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13